Defined HMO isomers • Fucosylated and sialylated targets • Research panels
BOC Sciences supports human milk oligosaccharide synthesis for microbial-interaction, pathogen-adhesion, receptor-recognition, and analytical research. Targets include 2'-fucosyllactose, 3-fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose, 3'-sialyllactose, 6'-sialyllactose, and specified extended HMOs. Linkage identity, reducing-end state, final derivative, and the evidence needed to distinguish related isomers are established for each material.
The requested HMO comparison pairs. Fucose position, terminal galactose linkage, and sialic-acid linkage distinguish each pair; exact sequences are provided in the table.Project specification
Custom synthesis scope
Closely related HMOs can share a composition while differing in a biologically important linkage or attachment position. A project specification pairs the familiar abbreviation with an explicit sequence and final material form.
Discuss 2'-FL with Fuc alpha1,2 linked to the galactose of lactose, or 3-FL with Fuc alpha1,3 linked to the glucose residue. These are different positional structures despite sharing monosaccharide composition. A comparison panel identifies each material separately and aligns purity, reducing-end state, and any derivatization.
Plan LNT with terminal Gal beta1,3 linked to GlcNAc, or LNnT with terminal Gal beta1,4 linked to GlcNAc. Both retain the lactose-based reducing-end sequence specified below. The type-1/type-2 terminal distinction is not resolved by intact mass alone and remains part of the structural evidence requirement.
Prepare specified Neu5Ac-containing sialyllactose with alpha2,3 or alpha2,6 linkage to the galactose of lactose. The sialic-acid identity, salt form where relevant, and final handling requirements are recorded. Synthesis and isolation must preserve the desired sialylated product and distinguish residual lactose or other related species.
Assess larger lactose-based structures, branching, combined fucosylation or sialylation, and specified labels or attachment groups. Expanded targets require a complete drawing rather than a broad request for complex HMOs. A derivative is identified separately from the corresponding free HMO because its reducing end or presentation may influence use.

Target-specific route assessment
Chemical, enzymatic, and chemoenzymatic routes offer different ways to reach HMO structures. The practical choice depends on linkage selectivity, precursor availability, enzyme substrate scope, final format, and the scale required for the particular study.
The route begins with the correct lactose-based acceptor or a suitable protected precursor. LNT and LNnT require different terminal galactose connections. Larger structures also require branch and extension order to be defined before selecting the assembly sequence.
Fucosyltransferases and sialyltransferases provide linkage-specific options when the intended acceptor is accepted. Activity depends on the actual substrate, derivatization, and reaction conditions. Literature demonstrations support route assessment without establishing that every extended or labeled analog will be converted efficiently.
Purification is planned for the HMO and its likely residual lactose, partial-extension products, salts, nucleotide-related materials, or isomers. Sensitive sialylated structures and final labels may require different processing conditions. The analytical record describes the isolated final product rather than only reaction conversion.
Material and project decisions
Sequences are written from the nonreducing side toward reducing-end glucose. Parentheses identify the fucose branch in 3-FL. A free reducing end can mutarotate; that behavior is distinct from an unintended linkage isomer.
| HMO | Linkage-defined sequence | Distinguishing feature |
|---|---|---|
| 2'-FL | Fuc alpha1-2 Gal beta1-4 Glc | Fucose is attached to galactose O2 |
| 3-FL | Gal beta1-4 (Fuc alpha1-3) Glc | Fucose is attached to glucose O3 |
| LNT | Gal beta1-3 GlcNAc beta1-3 Gal beta1-4 Glc | Terminal type-1 Gal beta1-3 GlcNAc unit |
| LNnT | Gal beta1-4 GlcNAc beta1-3 Gal beta1-4 Glc | Terminal type-2 Gal beta1-4 GlcNAc unit |
| 3'-SL | Neu5Ac alpha2-3 Gal beta1-4 Glc | Sialic acid is attached to galactose O3 |
| 6'-SL | Neu5Ac alpha2-6 Gal beta1-4 Glc | Sialic acid is attached to galactose O6 |
Our broader Glycan Synthesis Services support related defined oligosaccharide projects. For attached HMO formats, discuss the reducing-end chemistry and intended display through Glycan Conjugation Services.
Structure-to-data consistency
A mass match does not distinguish 2'-FL from 3-FL, LNT from LNnT, or 3'-SL from 6'-SL. The characterization plan combines structural identity, separation, and final-form information appropriate to each target.
Composition
Appropriate mass analysis supports the residue composition and any label or attachment group. Isomeric HMOs can share the same mass, so composition evidence is interpreted alongside linkage-sensitive data. Salt forms and relevant adducts are considered for sialylated targets.
Linkages
Suitable NMR, fragmentation, enzymatic, or reference-based evidence is selected for the structure. The package identifies how the fucose position, terminal Gal linkage, or sialic-acid linkage is supported. A retention time without a suitable reference and method context is not a universal structural assignment.
Purity
Chromatographic methods are selected to detect relevant precursor and product species. Reported area purity is tied to the detector and separation achieved. Quantitative assay, water, salt, or residual measurements are additional specifications where the study requires them; area purity is not interchangeable with dry-mass content.
Use format
Free HMOs and reducing-end derivatives are documented as distinct materials. A label can change recognition or microbial utilization, so final format is chosen with the assay. Research synthesis does not establish food-grade status, infant-nutrition suitability, or nutritional efficacy.
Research applications
HMO panels can isolate linkage and terminal-modification effects in controlled experiments. Outcomes depend on the microbial strain, binding partner, assay conditions, and molecular presentation.
Compare individual HMOs as specified substrates or interaction probes in defined microbial systems. Residual lactose or other utilizable sugars can confound interpretation, so relevant impurities and concentration basis should be included in the specification. Utilization by one strain does not establish a universal microbiome effect.
Investigate whether a defined HMO alters binding in a selected adhesion model. Include appropriate HMO isomers and assay controls. An in vitro adhesion result does not establish prevention of infection or a clinical benefit.
Use linkage-defined pairs to investigate fucose- or sialic-acid-dependent recognition. Match reducing-end state, linker, and display across derivatives where possible. Binding behavior in a multivalent format may differ from the free HMO.
Discuss structurally assigned materials for method development, retention comparisons, and isomer discrimination. A research reference is not automatically a certified reference material. Quantitative use requires an appropriate content value, uncertainty, and qualification scope.
A defined synthesis project
The project aligns familiar HMO names with exact structures, expected interfering species, and the requirements of the intended study.
Project brief
Provide the HMO names and sequences, free or derivatized reducing end, comparison isomers, amounts, assay type, and required identity, content, or residual tests.

Resolve abbreviations, terminal linkages, branches, and sialic-acid identity. Define the delivered reducing-end form.

Choose the comparison pairs and any lactose or related-oligosaccharide controls needed to interpret the experiment.

Review chemical or enzymatic routes, substrate acceptance, product sensitivity, and removal of relevant precursors or related species.

Isolate the materials and collect composition, linkage-sensitive identity, and separation data. Add content or residual tests when specified.

Provide member-specific analytical documentation and handling information. Identify research references and optional functional studies according to their agreed scope.
Project advantages
BOC Sciences scopes HMO materials around the exact isomer and analytical resolution required for the research comparison.
Common HMO abbreviations are paired with complete sequences and final material forms.
Residual lactose, partial extension, and related structures are considered in purification and analytical specifications.
Free or functionalized formats can be coordinated across the selected members, with biological interpretation kept tied to the tested system.
One connected glycan platform
Related insights
Explore supporting information on synthesis, characterization, and material selection for your project.
Frequently asked questions
Answers to common questions about the requested structures, characterization, and project scope.
Yes. List 2'-FL, 3-FL, LNT, LNnT, 3'-SL, and 6'-SL individually with amounts, final formats, and analytical requirements. Each is a separate target even where a pair shares its composition.
LNT contains a terminal Gal beta1,3 GlcNAc unit, whereas LNnT contains Gal beta1,4 GlcNAc. The remaining lactose-based sequence must also be specified. Their intact masses alone do not distinguish the terminal linkage.
In 2'-FL, fucose is alpha1,2 linked to the galactose residue of lactose. In 3-FL, fucose is alpha1,3 linked to the glucose residue. The attachment residue and position both matter.
A label or linker may change reducing-end chemistry, presentation, recognition, or utilization. Specify the intended assay and include suitable controls rather than assuming identical behavior.
Neither status follows from the structural name or research synthesis. Food-grade supply and certified quantitative references require additional manufacturing, testing, and qualification requirements. State the required use and evidence package explicitly.
Define the research material your project needs
Send your HMO list and exact sequences to BOC Sciences, including comparison isomers, final reducing-end format, amounts, and intended study. Identify any content, residual-lactose, or additional analytical requirements. We can assess a route and documentation package for the defined HMO materials your interaction or analytical research needs.
Contact BOC Sciences to discuss target-specific feasibility, specifications, and the required analytical package. Materials are intended for research use.